Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: www.femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

BearishAlgo Sep. 9 at 8:05 AM

$FEMY

0 · Reply

sn0wball Sep. 9 at 4:35 AM

$FEMY one last thing. price target 8-12$.

0 · Reply

sn0wball Sep. 9 at 4:13 AM

$FEMY Femasys has already started the pivotal trial for the FemBloc® system, which is a crucial step in the FDA approval process. They received FDA approval for an Investigational Device Exemption (IDE), allowing them to conduct this trial in the United States.

0 · Reply

sn0wball Sep. 9 at 4:11 AM

$FEMY Femasys is currently selling the FemBloc® system in Europe. They have secured their first order for FemBloc from distribution partners in Spain, valued at approximately $400,000. This marks the beginning of their commercial efforts in the European market following the recent CE mark approval. not advice...

0 · Reply

sn0wball Sep. 9 at 4:10 AM

$FEMY Femasys has successfully secured a CE mark for FemBloc, allowing it to be marketed across the European Economic Area, which includes 27 EU member states and three European Free Trade Association countries. according to AI, do your DD.

0 · Reply

sn0wball Sep. 9 at 4:09 AM

$FEMY know what you hold, FemBloc® system has received regulatory approval in certain regions outside the United States. Specifically, it has been granted a CE mark in Europe, which allows it to be marketed and sold in the European Economic Area. Additionally, FemBloc has also received approval in New Zealand.

0 · Reply

Samuelstark Sep. 9 at 12:43 AM

$FEMY

0 · Reply

YearOfTheRabbit Sep. 8 at 11:22 PM

$FEMY i bought and sold a couple times today bought again and holding i think k a big but short lived squeeze coming tomorrow

1 · Reply

Arcides Sep. 8 at 10:16 PM

$FEMY

1 · Reply

goldenxb Sep. 8 at 10:08 PM

$FEMY OK screw it I’m getting back in tomorrow 😂

1 · Reply

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 14 days ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 8, 2025, 4:05 PM EDT - 4 weeks ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 6, 2025, 9:00 AM EDT - 4 weeks ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 1, 2025, 9:00 AM EDT - 2 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 2 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 2 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 3 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 3 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 4 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 5 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 19, 2025, 9:20 AM EDT - 6 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 6 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 6 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 6 months ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 7 months ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 7 months ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 8 months ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 10 months ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 10 months ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 1, 2024, 8:30 AM EDT - 11 months ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 11 months ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 6, 2024, 9:00 AM EST - 1 year ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Feb 28, 2024, 9:00 AM EST - 1 year ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 6, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Jan 26, 2024, 8:00 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 23, 2024, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Dec 15, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Nov 30, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Nov 28, 2023, 8:40 AM EST - 1 year ago

Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner

Nov 28, 2023, 8:30 AM EST - 1 year ago

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

Nov 15, 2023, 8:30 AM EST - 1 year ago

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

PMCB

BearishAlgo Sep. 9 at 8:05 AM

$FEMY

0 · Reply

sn0wball Sep. 9 at 4:35 AM

$FEMY one last thing. price target 8-12$.

0 · Reply

sn0wball Sep. 9 at 4:13 AM

0 · Reply

sn0wball Sep. 9 at 4:11 AM

0 · Reply

sn0wball Sep. 9 at 4:10 AM

0 · Reply

sn0wball Sep. 9 at 4:09 AM

0 · Reply

Samuelstark Sep. 9 at 12:43 AM

$FEMY

0 · Reply

YearOfTheRabbit Sep. 8 at 11:22 PM

$FEMY i bought and sold a couple times today bought again and holding i think k a big but short lived squeeze coming tomorrow

1 · Reply

Arcides Sep. 8 at 10:16 PM

$FEMY

1 · Reply

goldenxb Sep. 8 at 10:08 PM

$FEMY OK screw it I’m getting back in tomorrow 😂

1 · Reply

HorrMoans Sep. 8 at 8:57 PM

$FEMY Called wash outs or wash sales. It’s the MMs keeping it down. Wait them out. At some point they get washed out with legitimate sales from whales and high volume.

1 · Reply